PNPedro Aleixo Nogueira

Pedro Aleixo Nogueira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Aleixo Nogueira has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognosis of intracranial meningiomas with TERTp mutation: Systematic review with meta-analysis

    by Giovana Clausson Bitolo, Christopher Aquino Pereira Lima, Pedro Aleixo Nogueira, Bianca Gomes Wanderley, Mateus Dal Fabbro, Marcos Vinícius Calfat Maldaun, Cleiton Formentin

    Background: Telomerase reverse transcriptase promoter (TERTp; C228T/C250T) mutations are incorporated into the World Health Organization 2021 classification of meningiomas (20%-30% in grade 3) as criteria for higher-grade designation, despite heterogeneous evidence regarding their independent prognostic value. Objectives: To evaluate the association between TERTp mutations and overall survival (OS) and progression-free survival (PFS) in patients with intracranial meningiomas. Methods: A systematic review and meta-analysis of clinical-pathological cohort studies comparing TERTp-mutated and wild-type meningiomas was conducted. Studies were identified through searches of PubMed, Embase, and Web of Science. Survival outcomes were synthesized using hazard ratios (HRs) and median survival estimates. Results: Thirteen studies were included. Meta-analyses comprised 4 studies for PFS by HR, 5 for OS by HR, 5 for PFS by mean difference (MD) (8 comparisons), and 5 for OS by MD. Sensitivity analyses excluded Maas et al. (2021), Spiegl-Kreineck et al. (2018), and Mellai et al. (2021) from the PFS mean-difference, OS HR, and OS mean-difference models, respectively; no study was excluded from the PFS HR model. Conclusions: Telomerase reverse transcriptase promoter mutations identify a biologically aggressive meningioma subgroup with markedly reduced survival, supporting their role as prognostic biomarkers. However, their isolated use for tumor reclassification should be interpreted cautiously and integrated with additional molecular features. Registration: PROSPERO platform (No. CRD420251135452).